<DOC>
	<DOC>NCT02104141</DOC>
	<brief_summary>The purpose of this combination retrospective and prospective post market study is to examine the short term safety and efficacy of the ROI-A® interbody fusion device with VerteBRIDGE® plates to treat single and two-level degenerative disc disease between L2 and S1, with a focus on fusion rates and patient outcomes.</brief_summary>
	<brief_title>Retrospective/Prospective Data Collection on the LDR ROIA Interbody Fusion Device With VerteBRIDGE Plating</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>Subjects must have degenerative disc disease (DDD) of the lumbar spine between L2 and S1 Subjects may have up to a Grade 1 spondylolisthesis at the involved level(s) Subject must have the ROIA® device at one level or at two contiguous levels between L2 and S1 only Subject should have had a minimum of 6 months nonsurgical treatment prior to receiving the ROIA® device Subject may have had NO MORE THAN two previous nonfusion surgeries to the lumbar spine at the same levels as the ROIA® Subject must be at least 21 years of age at the time of surgery Subject must be willing to signed an informed consent document and return for a 12 month visit Subject had more than Grade 1 spondylolisthesis at the operated level Subject is a prisoner. Subject was pregnant at the time of surgery. Subject had an active infection or sepsis at the time of surgery.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>DDD</keyword>
	<keyword>lumbar spine</keyword>
	<keyword>fusion rate</keyword>
	<keyword>degenerative disc disease</keyword>
</DOC>